Profile data is unavailable for this security.
About the company
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
- Revenue in USD (TTM)20.72m
- Net income in USD-100.84m
- Incorporated2015
- Employees147.00
- Location4D Molecular Therapeutics Inc5858 Horton Street #455, EmeryvilleEMERYVILLE 94608United StatesUSA
- Phone+1 (510) 505-2680
- Fax+1 (302) 655-5049
- Websitehttps://4dmoleculartherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collegium Pharmaceutical Inc | 566.77m | 48.16m | 1.23bn | 197.00 | 42.52 | 6.12 | 6.21 | 2.16 | 0.8823 | 0.8823 | 12.53 | 6.13 | 0.4891 | 6.10 | 3.13 | 2,876,990.00 | 4.16 | 2.79 | 6.75 | 4.80 | 57.55 | 50.88 | 8.50 | 5.16 | 1.10 | 2.59 | 0.7734 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| Prothena Corporation PLC | 91.37m | -147.03m | 1.23bn | 173.00 | -- | 2.19 | -- | 13.48 | -2.80 | -2.80 | 1.68 | 10.46 | 0.1256 | -- | -- | 528,150.30 | -20.22 | -14.20 | -21.82 | -15.11 | -- | -- | -160.92 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| Pacira Biosciences Inc | 674.98m | 41.96m | 1.27bn | 711.00 | 40.08 | 1.45 | 10.77 | 1.88 | 0.6789 | 0.6789 | 12.33 | 18.72 | 0.4147 | 1.84 | 6.62 | 949,336.10 | 2.58 | 3.35 | 2.79 | 3.98 | 72.64 | 72.63 | 6.22 | 8.57 | 4.17 | 9.85 | 0.3752 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Belite Bio Inc (ADR) | 0.00 | -31.63m | 1.29bn | 20.00 | -- | 13.93 | -- | -- | -1.24 | -1.24 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -45.54 | -- | -47.50 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 442.74m | -1.00bn | 1.29bn | 267.00 | -- | -- | -- | 2.92 | -6.51 | -6.51 | 2.59 | -2.21 | 0.5634 | -- | 3.62 | 1,658,184.00 | -131.28 | -4.54 | -162.45 | -5.20 | -- | -- | -233.00 | -7.81 | -- | 63.79 | 1.98 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Gyre Therapeutics Inc | 0.00 | -44.24m | 1.29bn | 7.00 | -- | -- | -- | -- | -20.60 | -20.60 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -215.90 | -58.25 | -235.61 | -72.12 | -- | -- | -- | -817.06 | -- | -- | 0.00 | -- | -89.18 | -4.85 | 90.63 | -- | -- | -- |
| Spyre Therapeutics Inc | 886.00k | -338.79m | 1.31bn | 30.00 | -- | -- | -- | 1,478.04 | -75.04 | -75.04 | 0.1285 | 7.45 | 0.0043 | -- | 4.73 | 29,533.33 | -164.06 | -101.87 | -184.94 | -118.83 | -- | -- | -38,238.15 | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
| Ligand Pharmaceuticals Inc | 131.31m | 53.82m | 1.33bn | 58.00 | 25.42 | 1.85 | 14.69 | 10.11 | 2.91 | 2.81 | 7.26 | 39.92 | 0.1695 | 0.5642 | 4.15 | 2,264,035.00 | 6.94 | 12.32 | 7.50 | 12.99 | 91.99 | 81.65 | 40.98 | 80.32 | 12.72 | -- | 0.00001 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| 4D Molecular Therapeutics Inc | 20.72m | -100.84m | 1.35bn | 147.00 | -- | 3.69 | -- | 65.12 | -2.58 | -2.58 | 0.5438 | 7.15 | 0.0689 | -- | -- | 140,972.80 | -33.52 | -32.67 | -35.57 | -34.90 | -- | -- | -486.59 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Akero Therapeutics Inc | 0.00 | -151.76m | 1.36bn | 55.00 | -- | 2.05 | -- | -- | -2.85 | -2.85 | 0.00 | 9.60 | 0.00 | -- | -- | 0.00 | -32.40 | -37.73 | -33.78 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0446 | -- | -- | -- | -35.46 | -- | -- | -- |
| Tarsus Pharmaceuticals Inc | 17.45m | -135.89m | 1.39bn | 244.00 | -- | 6.40 | -- | 79.79 | -4.58 | -4.58 | 0.5939 | 5.76 | 0.0707 | -- | 1.64 | 71,504.10 | -55.09 | -31.56 | -61.63 | -33.82 | 90.87 | -- | -778.89 | -242.59 | 6.85 | -- | 0.1315 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| ANI Pharmaceuticals Inc | 486.82m | 15.48m | 1.41bn | 642.00 | 81.92 | 3.18 | 18.34 | 2.90 | 0.821 | 0.821 | 26.17 | 22.35 | 0.5849 | 1.68 | 2.97 | 758,280.40 | 2.26 | -2.83 | 2.65 | -3.35 | 62.71 | 60.18 | 3.86 | -6.15 | 2.81 | 1.79 | 0.3843 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Vir Biotechnology Inc | 86.18m | -615.06m | 1.41bn | 587.00 | -- | 0.8806 | -- | 16.38 | -4.59 | -4.59 | 0.6425 | 11.80 | 0.0365 | -- | -- | 146,814.30 | -26.06 | -0.6081 | -30.49 | -0.7192 | 96.79 | -- | -713.76 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Kiniksa Pharmaceuticals Ltd | 301.77m | 8.65m | 1.42bn | 297.00 | 235.68 | 3.29 | 131.16 | 4.72 | 0.0852 | 0.0852 | 4.16 | 6.10 | 0.627 | 1.46 | 25.77 | 1,016,067.00 | 1.80 | -16.49 | 2.01 | -18.72 | 87.75 | -- | 2.87 | -53.64 | 3.79 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
| Arcus Biosciences Inc | 117.00m | -307.00m | 1.43bn | 577.00 | -- | 2.57 | -- | 12.20 | -4.15 | -4.15 | 1.58 | 6.12 | 0.0959 | -- | 2.89 | 202,773.00 | -25.16 | -15.85 | -29.76 | -18.25 | -- | -- | -262.39 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
Data as of May 06 2024. Currency figures normalised to 4D Molecular Therapeutics Inc's reporting currency: US Dollar USD
53.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Viking Global Investors LPas of 04 Jan 2024 | 4.25m | 8.53% |
| RA Capital Management LPas of 31 Dec 2023 | 4.16m | 8.36% |
| BVF Partners LPas of 31 Dec 2023 | 4.01m | 8.05% |
| Janus Henderson Investors US LLCas of 31 Dec 2023 | 3.08m | 6.19% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.93m | 5.89% |
| Deep Track Capital LPas of 31 Dec 2023 | 2.28m | 4.59% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.82m | 3.65% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.52m | 3.06% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.48m | 2.98% |
| ArrowMark Colorado Holdings LLCas of 31 Dec 2023 | 1.20m | 2.41% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
